Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review - Quiz - MDSpire

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • By

  • Xin Shen

  • Jiangnan Yang

  • Yang Du

  • Deyuan Fu

  • June 4, 2026

  • 0 min

Share

Original Source(s)

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • by Xin Shen, Jiangnan Yang, Yang Du, Deyuan Fu

  • June 4, 2026

Related Content

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk

The intratumoral microbiome: a review of the tumor microenvironment’s fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response